Funding news
Phoenestra GmbH logo

Phoenestra GmbH Raises $190

Recently funded · $190.0M Series aHospitals and Health CareATView source

Get the full Phoenestra GmbH company profile

Access contacts, investors, buying signals & more

Open in Dashboard

The burgeoning field of stem cell therapeutics just saw a significant infusion of capital, with Phoenestra GmbH announcing a $190.0M Series A round. The German company is building out an end-to-end approach for a broad range of stem cell-derived products, from xeno-free induced pluripotent stem cell lines to extracellular vesicle preparations.

Phoenestra is establishing GMP laboratories for cell banking and manufacturing of (pre-)clinical study material, aiming to develop stem cell-derived therapeutic modalities. The Series A capital will support its work on engineered "universal" stem cell lines and iPS cell-derived differentiated cells, both currently in development.

Other Austria companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series a rounds

Companies that recently closed a Series a round.

#CompanyAmount
1
Solarstream Limited logo

Solarstream Limited

Ireland

$12.5M
2
Zodia Custody logo

Zodia Custody

United Kingdom

$15.0M
3
Myota logo

Myota

United States

$7.7M
4
WAYOUT WATER logo

WAYOUT WATER

Sweden

$2.8M
5
GrailPay logo

GrailPay

United States

$10.5M